Intuitive Surgical (NASDAQ:ISRG) Stock: Insider Patricia Wadors Sells 1,078 Shares

Key Points

• Insider sale: SVP Patricia Wadors sold 1,078 Intuitive Surgical shares for approximately $478,416 at an average price of $443.80. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Strong quarterly results: Intuitive Surgical reported quarterly revenue of $3.05 billion, up 21.7% year over year, and EPS of $3.00, exceeding analysts’ $2.65 consensus estimate.
• Analyst outlook remains positive: The stock carries a “Moderate Buy” consensus rating with an average price target of $493.54, although its premium valuation—with a P/E ratio above 54—may keep investors cautious.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) SVP Patricia Wadors sold 1,078 shares of the firm's stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $443.80, for a total transaction of $478,416.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Price Performance

NASDAQ ISRG traded down $0.66 on Monday, reaching $451.63. The company had a trading volume of 2,916,696 shares, compared to its average volume of 2,433,892. The firm has a market capitalization of $156.55 billion, a PE ratio of 54.61, a P/E/G ratio of 3.12 and a beta of 1.46. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The firm has a 50-day moving average of $395.50 and a 200-day moving average of $408.83.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm had revenue of $3.05 billion during the quarter, compared to analysts' expectations of $2.91 billion. During the same quarter in the prior year, the firm earned $2.40 EPS. Intuitive Surgical's quarterly revenue was up 21.7% on a year-over-year basis. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ISRG shares. Evercore set a $430.00 price objective on Intuitive Surgical in a research note on Monday, July 6th. JPMorgan Chase & Co. upped their target price on Intuitive Surgical from $450.00 to $475.00 and gave the company an "overweight" rating in a report on Wednesday, October 21st. Piper Sandler reissued an "overweight" rating on shares of Intuitive Surgical in a research report on Friday, August 21st. Citigroup decreased their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating for the company in a report on Friday, July 17th. Finally, KeyCorp reiterated an "overweight" rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $493.54.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts and market commentators continue to view Intuitive Surgical as a strong growth company, citing durable demand for robotic-assisted surgery and potential for the stock to outperform the broader market. Intuitive Surgical Is an Incredible Growth Stock: 3 Reasons Why
• Positive Sentiment: Higher earnings estimates are providing a near-term bullish catalyst. The revisions suggest analysts are becoming more optimistic about ISRG’s financial outlook, potentially supporting further gains. Earnings Estimates Moving Higher for Intuitive Surgical
• Neutral Sentiment: ISRG is receiving elevated investor attention across financial websites, but the “trending stock” coverage is primarily informational rather than a new business or earnings announcement. Intuitive Surgical Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Commentary is also addressing whether Intuitive Surgical’s premium valuation is justified. This may keep investors selective even as the company’s long-term growth story remains intact. If Intuitive Surgical Stock Looks Expensive, You Need To Read This
• Negative Sentiment: Director Gary Guthart sold 20,095 shares for approximately $9.1 million, reducing his direct ownership by 1.64%. Because the sale was made under a pre-arranged Rule 10b5-1 plan, it may not reflect a change in the company’s outlook, but insider selling can still weigh on sentiment. SEC Insider Transaction Filing

Institutional Investors Weigh In On Intuitive Surgical

Large investors have recently bought and sold shares of the company. Plato Investment Management Ltd acquired a new stake in shares of Intuitive Surgical during the 2nd quarter worth about $4,315,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Intuitive Surgical during the 2nd quarter worth about $14,316,000. Hikari Power Ltd acquired a new position in Intuitive Surgical in the 2nd quarter valued at about $5,619,000. NewEdge Advisors LLC grew its stake in Intuitive Surgical by 19.1% in the 2nd quarter. NewEdge Advisors LLC now owns 50,825 shares of the medical equipment provider's stock valued at $20,212,000 after buying an additional 8,142 shares during the last quarter. Finally, Nykredit A S acquired a new position in Intuitive Surgical in the 2nd quarter valued at about $48,464,000. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.